These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 22685162)

  • 1. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
    Jakobsen L; Cattoir V; Jensen KS; Hammerum AM; Nordmann P; Frimodt-Møller N
    J Antimicrob Chemother; 2012 Oct; 67(10):2438-44. PubMed ID: 22685162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.
    Domínguez-Herrera J; Velasco C; Docobo-Pérez F; Rodríguez-Martínez JM; López-Rojas R; Briales A; Pichardo C; Díaz-de-Alba P; Rodríguez-Baño J; Pascual A; Pachón J
    J Antimicrob Chemother; 2013 Jul; 68(7):1609-15. PubMed ID: 23493313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.
    Allou N; Cambau E; Massias L; Chau F; Fantin B
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4292-7. PubMed ID: 19635960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High percentage of resistance to ciprofloxacin and qnrB19 gene identified in urinary isolates of extended-spectrum beta-lactamase-producing Escherichia coli in Madrid, Spain.
    Ríos E; Rodríguez-Avial I; Rodríguez-Avial C; Hernandez E; Picazo JJ
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):380-3. PubMed ID: 20638608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model.
    Vellinga A; Tansey S; Hanahoe B; Bennett K; Murphy AW; Cormican M
    J Antimicrob Chemother; 2012 Oct; 67(10):2523-30. PubMed ID: 22729920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli.
    Machuca J; Briales A; Labrador G; Díaz-de-Alba P; López-Rojas R; Docobo-Pérez F; Martínez-Martínez L; Rodríguez-Baño J; Pachón ME; Pascual A; Rodríguez-Martínez JM
    J Antimicrob Chemother; 2014 Dec; 69(12):3203-15. PubMed ID: 25139837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes.
    Cesaro A; Bettoni RR; Lascols C; Mérens A; Soussy CJ; Cambau E
    J Antimicrob Chemother; 2008 May; 61(5):1007-15. PubMed ID: 18325893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections.
    Casellas JM; Tome G; Exeni R; Grimoldi I; Goldberg M; Farinati AE
    Pathol Biol (Paris); 1993 Apr; 41(4):385-91. PubMed ID: 8233640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose.
    Boy D; Well M; Kinzig-Schippers M; Sörgel F; Ankel-Fuchs D; Naber KG
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S6-16. PubMed ID: 15037323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.
    van der Starre WE; van Nieuwkoop C; Paltansing S; van't Wout JW; Groeneveld GH; Becker MJ; Koster T; Wattel-Louis GH; Delfos NM; Ablij HC; Leyten EM; Blom JW; van Dissel JT
    J Antimicrob Chemother; 2011 Mar; 66(3):650-6. PubMed ID: 21123286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition.
    Smith SP; Manges AR; Riley LW
    Clin Infect Dis; 2008 Mar; 46(5):689-95. PubMed ID: 18230040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates.
    Lin CY; Huang SH; Chen TC; Lu PL; Lin WR; Chen YH
    J Microbiol Immunol Infect; 2008 Aug; 41(4):325-31. PubMed ID: 18787740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli.
    Martín-Gutiérrez G; Rodríguez-Beltrán J; Rodríguez-Martínez JM; Costas C; Aznar J; Pascual Á; Blázquez J
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4252-8. PubMed ID: 27139482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
    Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.
    So W; Crandon JL; Nicolau DP
    J Urol; 2015 Aug; 194(2):563-70. PubMed ID: 25637857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Cafini F; Valero E; Relaño MT; Prieto J
    J Antimicrob Chemother; 2006 Apr; 57(4):714-9. PubMed ID: 16492718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.